Growing Number of Heart Failure Incidences to Augment Demand for Dilated Cardiomyopathy Medications

Dilated cardiomyopathy has led to an increase in heart failures worldwide among adults and children also giving rise to need for heart transplant. Dilated cardiomyopathy can develop between the ages of 20 and 40 years, genetic inheritance being the most common factor affecting 30%-40% of the DCM patients globally. Due to the increasing cases of heart failures, the demand for dilated cardiomyopathy drugs is expected to increase as the need for blockbuster drugs in developed countries is becoming evident. 

According to a report published by Transparency Market Research, the global dilated cardiomyopathy therapeutics market is expected to witness a negative CAGR of -7% from 2014 to 2020. The global dilated cardiomyopathy market was valued at US$651 mn in 2013 and is projected to decrease to US$328.6 mn by 2020. 

Browse Report: 

http://www.transparencymarketresearch.com/dilated-cardiomyopathy-market.html

How can an increase in heart failure cases help drug manufacturers to develop innovative and advanced therapeutics?

According to a study, in every one million children across the globe, six are diagnosed with dilated cardiomyopathy. It is found commonly among children who are under the age of 2 years. There has also been a substantial increase in the number of heart failures among adults as well, leading to a global rise in the demand for dilated cardiomyopathy therapeutics. Of the overall congestive heart failures that occur each year, DCM comprises 30%-40%. Due to this, several leading companies have introduced clinical trials and invested for the development of therapeutics for dilated cardiomyopathy. 

For instance, Cincinnati Children’s Heart Institute announced a breakthrough development on 19 May, 2016 where genetically inherited heart diseases can be diagnosed and treated with the help of biomechanics and stem cells. Similar breakthroughs are underway in the field of dilated cardiomyopathy drugs to help in the growth of the market with better techniques and medications. 

What factors are responsible for the negative growth of the dilated cardiomyopathy therapeutics market?

 DCM drugs segment has no drug that has been approved by FDA till date. The drugs used for the treatment of dilated cardiomyopathy and congestive heart failure are same and have no distinct formulation. DCM drugs are reported to have side effects and this has thus affected revenues from DCM therapeutics substantially. The use of devices and gene therapy that provide enhanced relief without any side effect has highly restrained the dilated cardiomyopathy therapeutics market growth globally.

However, companies in the DCM drug market along with research organizations are working on the approval of aldosterone antagonists combined with ARBs or ACE. It is expected that these drugs will play a positive role in reducing the progress of Duchenne muscular dystrophy. This approval will help in the acceleration of sales of DCM drugs as aldosterone antagonists are one of the main additives in the formulation of DCM medications. 

The increase in genericization activities of DCM drugs will also provide manufacturers with opportunities to improve their product position in the global market and also witness a positive growth of the DCM drugs market.

North America dominated the DCM drugs market in 2013 due to the demand for branded drugs and increasing heart failure cases. Asia Pacific is projected to be the fastest growing market for DCM followed by the Rest of the World owing to the per capita income increase, and improving economic standards in the region. Some of the key players operating in the global DCM drugs market are Celladon Corporation, Novartis International AG, Vericel Corporation, Sanofi S.A., AstraZeneca plc, and GlaxoSmithKilne plc.

Growing mHealth Infrastructure Propels Demand for Melanoma Detection Mobile Applications

Melanoma is a cancer of melanin-forming cells known as melanocytes and if not recognized and treated early, it can be fatal. During the recent years, a significant increase in melanoma cases has been witnessed in Europe and Israel. This growth can be attributed to greater UV exposure due to changing atmospheric conditions. The growing prevalence of melanoma coupled with the rising adoption of mHealth programs is bringing conducive growth opportunities to the melanoma detection mobile applications market in Israel and Europe.

How is European and Israel’s market responding to mobile applications for melanoma detection?

A rise in the cases of melanoma in European countries and in Israel has caused a surged in the demand for mobile applications for melanoma detection. As per a study by Transparency Market Research (TMR), the market in Europe and Israel is anticipated to grow at an impressive CAGR of 47% between 2014 and 2022, reaching a value of US$1.5 mn by 2022. 

Furthermore, a significant rise in the adoption of mHealth tools has attracted many companies to invest in this field. This has resulted in a highly fragmented market with high competition. Denmark, Norway, Switzerland, Sweden, the U.K., and the Netherlands are expected to be the key growth markets for mobile applications for melanoma detection in Europe in the near future.

How has technology helped in reducing the number of deaths due to melanoma?

Early detection is important in order to reduce the diagnosis and treatment difficulties. Skin surveillance conducted by healthcare experts or through skin self-examination (SSE) conducted by the individual can help in the prevention of melanoma. A spike in the number of patients participating in SSE through mobile applications has aided early detection and helped in reducing the mortality rate.

There are a number of applications such as educational applications, mole tracking and reminder applications, algorithm analysis applications, and interactive teaching applications available on different operating system stores. In the past few years, there has been an increased inclination towards mobile applications that send images of moles and patches to panels of certified dermatologists who inspect the respective images and issue the diagnosis. 

Browse Press Release:

http://www.transparencymarketresearch.com/pressrelease/europe-israel-mobile-applications-melanoma-detection-market.htm

What obstacles do companies face in generating revenues?

A number of mobile applications serving melanoma patients are available from different vendors/developers. Thus, there is a stiff competition among developers to gain more downloads and users. However, users show a lack of interest in using the paid/premium version of applications, which hinders revenue generation of the vendors.  To counter this, application developers are trying to develop alternative revenue models in order to generate profits. Some of the key players in the melanoma detection mobile applications market are Spot Mole, Dr. Mole, and Melanoma Watch.

Rising Geriatric Population will be a Pivotal Trend for Growth of Pain Management Therapeutics Market

The Rising incidence of chronic diseases can be attributed to aging population, increased population undergoing surgeries, changing lifestyles, and gradually changing environmental conditions. Researchers report that presently about 20% of the world’s population suffers from chronic pain. This accelerates the need for addressing chronic pain with a sophisticated and effective solution. As a result, the growth of the global pain management therapeutics market in the past few years has triggered and is poised to drive the market at an effective CAGR in the coming years.

High Prevalence of Chronic Diseases to Intensify the Growth of Pain Management Therapeutics Market

The number of patients suffering from chronic pain is increasing at an alarming rate. This has escalated the demand for pain management therapeutics. The mounting cases of cancer and diabetes further contributed to the expansion of global pain management therapeutics market. According to a report by World Health Organization (WHO), the number of new cancer cases is anticipated to grow by almost 70% across the globe. A surge in the number of cases of chronic back pain owing to rising geriatric population and hectic lifestyles will also enable lucrative growth of the global pain management therapeutics market.

Research Report: http://www.transparencymarketresearch.com/pain-management-therapeutics.html

Pain Management Industry to Benefit from Old Demographics

The rising prevalence of diseases such as arthritis, depression, diabetic neuropathy, epilepsy, joint or bone pain, and nerve damage can be attributed to the increasing geriatric population. Various studies suggest that by 2050, the age of nearly 22% of the projected global population will be more than 65. This demographic trend towards the older generation will lead to a notable rise in the demand for numerous pain management therapeutics, thereby boosting the growth of global pain management therapeutics market.

Favorable Regulatory Measures to Propel the Consumption of Pain Management Therapeutics

Regulatory framework plays a crucial role in the successful development, approval, and commercialization of numerous drugs in the pain management therapeutics sector. The intervention of regulatory firms that favor the deployment of instruments for the improved diagnosis and treatment of chronic pain and employment of methods for improvement of efficiency, will help global pain management therapeutics market in maintaining a substantial growth rate.

Need for Practical Substitutes to Passwords to Fuel the Demand for Biometrics in Healthcare Sector

The need to protect critical medical records and data in the healthcare sector has increased the demand for alternative solutions to passwords.  Biometrics is the most significant solution to curb the risk of data theft as biometric systems capture a unique physical feature of an individual, analyze it, and store them for future reference. The rising opportunities in the healthcare sector regarding the use of self-service biometric system are expected to bolster future growth prospects for the healthcare biometric market. 

According to a report published by Transparency Market Research, the global healthcare biometrics market is projected to expand at a 25.9% CAGR between 2013 and 2019. The global healthcare biometrics market was valued at US$1.2 bn in 2012 and is expected to reach US$5.8 bn by 2019. 

What factors lead to increasing deployment of biometric systems across the healthcare sector? 

The adoption of biometric system in the healthcare industry will not only prevent frauds but will also minimize data loss and wastage of resources. It will also enhance the safety, quality, and privacy of hospitals. The use of biometric system in hospitals to verify staff and patient data and also provides control over data access. This is likely to be one of the main reasons behind its growing demand.  Another advantage of biometric system is that they have very less set up cost and are accurate on the functional front. According to experts, expenses incurred during the installation and upkeep of biometric system are comparatively less than the expenses occurred during theft of medical data and security breach. 

How can new technological innovations used in biometrics system enhance growth opportunities for suppliers? 

The evolving technologies in biometrics system are expected to provide abundant growth opportunities to developers of biometric systems. The biometrics kiosk self-service system in healthcare sector is a breakthrough technology that vendors of biometrics can capitalize in future. Moreover, taking advantage of the potential opportunities, companies are investing on the development of automated biometrics with better response time and accuracy. The new market players are focusing on the reduction of cost and upgrading biometric security systems to make them more suitable for use in conferences, trade shows, web casting, laboratories, and electronic newsletter, to carve out new opportunities for themselves. The scope in verification of identity through biometric of the palm vein is also projected to augment the demand for biometric system in the healthcare system. 

However, concerns regarding biometrics template storage and security and convenience trade-off are likely to impede the growth of the healthcare biometric system market. 

The global healthcare biometric system market is dominated by North America at present and the region is anticipated to maintain its lead in the upcoming years. The TMR report states that Europe along with North America accounts for over 75% of the global share in the healthcare biometrics market. 

Browse Research Press Release:

http://www.transparencymarketresearch.com/pressrelease/healthcare-biometrics-industry.htm

Leading companies such as SAFRAN SA, Lumidigm Inc., Suprema Inc., BIO-key International, ZKTeco Inc., and Siemes AG are carrying out mergers and acquisitions and partnerships to keep pace with the dynamic nature of the market. The presence of various small and large companies has rendered the global healthcare biometric system market highly fragmented.

Increasing Incidence of Cancer Boosts Opportunities for Companies in Molecular Cytogenetics Industry

Molecular cytogenetics is used as a tool for the examination of chromosomal anomalies and research relating to these anomalies. This technique is chosen over the generic chromosomal banding methods as the old techniques deliver low resolution results and at times escape the detection of various variations. Breakthrough technologies such as aCGH and FISH are expected to provide new dimensions to the research and development projects in the field of molecular cytogenetics. 

According to a report published by Transparency Market Research, the global market for molecular cytogentics is projected to exhibit a CAGR of 23.40% from 2013 to 2019. The market stood at US$0.4 bn in 2012 and is likely to reach US$1.9 bn by 2019. 

How technological advancements fuel demand for molecular cytogentics?

As molecular cytogenetics is more dependable than the other traditional techniques used for the diagnosis of chromosomal abnormalities, the technological advancements in this segment are expected to spur the adoption of this technique in future. Breakthrough technologies such as aCGH and FISH are being considered as priceless tools for the analysis of complex diseases, gene discovery, and gene mapping. These techniques also facilitate the diagnosis of solid molecular tumors and hematological malignancies along with their prognosis. These techniques are also known for their speed, sensitivity, accuracy, and high resolution, which encourage healthcare providers to adopt them. The growing importance of molecular cytogentetics in laboratories has led to further advancements in the technique such as digital imaging and improvement in fluorescence microscopes. The implementation of these techniques in laboratories and diagnostic centers is expected to boost theor emand further in future.  

What factors are expected to drive the adoption of molecular cytogenetics across diagnostic centers and laboratories?

The introduction of advanced technologies in molecular cytogenetics diagnosis is expected to encourage more investments in the research and development projects by non-government and government institutions. As technological advancements increase, more institutions are adopting molecular cytogenetics to get appropriate and cost effective results regarding chromosomal anomalies. 

The rising incidences of cancer globally have also led to the adoption of molecular cytogenetics for its diagnosis. The growing awareness about chromosomal abnormalities among people and their inclination towards personalized medicines are also projected to drive the demand for molecular cytogenetics diagnosis. 

Browse Press Release:

http://www.transparencymarketresearch.com/pressrelease/molecular-diagnostics-market.htm

However, the easy accessibility of medical reimbursement policies and lack of transparency may hinder the growth of the molecular cytogenetics market in future. 

North America held the largest share in the global molecular cytogenetics market followed by Europe in 2012. The growing number of research laboratories in these regions is the major factor fuelling demand for molecular cytogenetics. Asia Pacific is projected to emerge as the fastest developing market for molecular cytogenetics due to rising population in the region. The leading companies in the market are entering into collaborations to carry out more researches in the segment. The key players operating in the molecular cytogenetics market are Abbott Laboratories, Oxford Gene Technology, Agilent Technologies, Bio-Rad Laboratories, and Illumina Inc.

Advent of Cognitive Learning to Revolutionize Development of E-Clinical Solution Software

E-clinical solution software comprises programs intended to make the process of data management in the global healthcare sector easier than can be done with conventional methods. The healthcare industry generates a massive volume of patient data every day, which requires careful storage in a way that also allows easy access for future use. The confidentiality of patient data also makes the storage system used for healthcare data crucial. This has driven the demand for digital data storage systems in the last few years and several major players have adopted various types of web-based e-clinical solution software to boost their productivity. 

According to Transparency Market Research, the global market for e-clinical solution software was valued at US$3 bn in 2014. Exhibiting a robust growth rate of 13.80% from 2014 to 2020, the market is expected to rise to a valuation of US$6.8 bn. 

How is cognitive learning impacting the global e-clinical solution software market?

One of the major points discussed at last month’s Digital Health Summer Summit in San Francisco was the potential applications of cognitive learning programs in the healthcare industry. While smart data logging and tracking software is becoming common in healthcare applications, the advent of cognitive learning in the field represents a crucial milestone for the industry.

Cognitive learning programs have the ability to not only organize and secure data, but also to come up with insights based on the data and to modify the conclusions when more data is added. This presents a major advancement for the healthcare industry owing to the increased accuracy and reliability cognitive learning solutions provide. 

Which is the most popular delivery mode for e-clinical solution software?

By delivery mode, the demand for web-based e-clinical solution software dominates the global market. However, cloud-based delivery of e-clinical solution software is expected to become increasingly popular in the coming years. While web-based data storage revolutionized the healthcare industry by demonstrating the benefits of digitization, cloud-based data storage represents the logical next step of outsourcing data storage services. Cloud-based delivery of e-clinical solution software allows the end users to focus their resources on improving their core operations, which has driven the demand for cloud services. 

Of the major end users of e-clinical solution software, the pharmaceutical industry took up the leading share in the global market in 2014. The consistent need for precise data in the pharmaceutical industry has made the sector a prominent end user of e-clinical solution software, with the increasing number of clinical trials expected to provide a major boost to the demand for e-clinical solution software in the coming years. However, clinical research organizations (CROs) are another major end user segment of the global e-clinical solution software market and are likely to exhibit the fastest growth in demand in the 2014-2020 forecast period.

Browse Research Release: 

http://www.transparencymarketresearch.com/pressrelease/global-e-clinical-solution-software-market.htm

What does the increasing number of clinical trials in Asia Pacific signify for the e-clinical solution software market?

Currently, North America is the global leader in the e-clinical solution software market and holds a share of close to 60% due to the strong presence of the pharmaceutical industry in the region. Nevertheless, the increasing population in Asia Pacific is expected to result in an increase in the demand for e-clinical solution software, with North America’s share expected to drop to about 55% by 2020. Several pharmaceutical and life sciences companies are setting a firm foothold in rampant Asia Pacific economies, where the demand for pharmaceutical products is likely to grow significantly in the coming years.

Increasing Research into Longer Lasting Peptide Therapeutics Set to Bear Fruit

Peptides are short-chain amino acids used therapeutically in the treatment and management of several diseases, including major killers such as diabetes. Peptides are differentiated from proteins by the length of their amino acids; proteins have longer amino acid chains than peptides. Peptides such as insulin have been in therapeutic use for a long time and have helped drive investment in research into the therapeutic efficacy of peptides. Due to the growing investment in the sector, peptide therapeutics are becoming increasingly important in the global healthcare sector. 

Browse Full Market Research Report: 

http://www.transparencymarketresearch.com/peptide-therapeutics-market.html

According to Transparency Market Research, the global peptide therapeutics market is expected to exhibit a low yet steady 2.8% CAGR between 2014 and 2020. The market’s valuation is expected to rise from US$18.9 bn in 2013 to a projected US$23.7 bn by the end of the forecast period. Apart from the established therapeutic uses of peptides, their potential use in the treatment of various cancers, neurological disorders, hematological disorders, and cardiovascular and respiratory disorders is expected to be crucial for the market’s growth in the forecast period. 

How important will the growing prevalence of diabetes be for the peptide therapeutics market?

Despite the increasing research into the use of peptides in the treatment of various other diseases, the use of insulin in diabetes management remains the key application of peptide therapeutics. Diabetes has not shown any signs of slowing down since insulin became the first therapeutically used peptide; in fact, its prevalence has grown rapidly in the last few decades, as the increasing prosperity in developed economies has made various risk factors for diabetes increasingly accessible to the average consumer. The disease is expected to remain a global healthcare concern in the coming years, driving the market for advanced insulin products.

Apart from the use of insulin in diabetes management, what is the key driver for the peptide therapeutics market?

The increasing innovation of advanced peptide therapeutics is another key driver for the global peptide therapeutics. As the infrastructure for clinical research into peptide therapeutics becomes more refined, the use of high-precision methods and tools has allowed market giants to come up with safe and effective peptide therapeutics. Due to the increasing consumer satisfaction brought about by technological progress, collaboration between biotech and pharmaceutical companies is expected to be a prominent feature of the global peptide therapeutics market in the coming years.

A key advancement in the field of peptide therapeutics is the innovation of stable peptide molecules that aren’t degenerated by the body as quickly as conventional peptides. The conventional mode of delivering peptide therapeutics has involved permeability enhancement, which comprises various techniques to ease the entry of the peptide into the vascular network around the digestive tract. However, most slow-acting peptide therapeutics fail to achieve significant bioavailability through this procedure. The promising recent development of a phase-II GLP-1 analog that has a circulating half life of around one week by Novo Nordisk could open the doors for peptide therapeutics to be used on a wider scale in the treatment of several other diseases.

Which region presents the most lucrative opportunities for producers of peptide therapeutics?

Even though North America and Europe currently account for a majority share in the global peptide therapeutics market, the future of the market is expected to be dominated by Asia Pacific. The medical research sector in Asia Pacific has undergone significant development in the last few years, and the high prevalence of diabetes in Asian races means peptide therapeutics are not an entirely novel field.

Government Support Crucial for Widespread Adoption of Stem Cell Therapy

Stem cells are a type of human cells that give rise to the various types of cells found in the human body. Stem cells hold the potential to evolve into various types of human tissue, which has led to a growing acknowledgement of the obvious medical potential of this property. Stem cell therapy is becoming increasingly common in the treatment of various diseases and the increasing research in the field is expected to further drive the medical applications of stem cells in the coming years.

According to Transparency Market Research, government support is expected to be crucial in the global stem cells market’s expected rise from a 2013 valuation of US$26.3 bn to a valuation of US$119.5 bn by 2018. The market is expected to exhibit a robust 24.2% CAGR between 2012 and 2018.

Download Complete Healthcare Analytical Brochure: 
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=132

What are the major advances in the field of stem cells and their medical application?

In July 2016, a joint Dutch-Canadian research effort succeeded in discovering a viable method of increasing the amount of stem cells obtained from cord blood. Cord blood, which is blood from the placenta, contains a relatively small amount of stem cells per unit. The method formulated in the research allows researchers to increase the amount of stem cells obtained from cord blood, making this is a crucial advancement in the field of stem cell therapy. 

The team discovered that mirR-125a, a microRNA, is responsible for the property of stem cells to self-renew. This genetic ‘switch’ remains activated in stem cells but is inactivated in the progenitor cells formed from the division of stem cells. Success in activating this switch would result in self-sustaining production of stem cells, which will be a major boost for the global stem cell therapy market.

In April this year, a research team at McMaster University in Hamilton, Ontario, discovered the protein responsible for the growth and development of blood stem cells. The Musashi-2 protein could be the key to helping thousands of patients of various blood disorders, as understanding the ambit of the protein could allow researchers to increase the number of viable stem cells available for therapeutic use.

What are some of the major drivers for the stem cells market?

The key driver for the global stem cells market is the increasing government support across the world. As widespread incorporation of stem cell therapy allows a nation to significantly improve the overall healthcare scenario, countries in North America and Western Europe have provided solid support to stem cell research. The acceptance of stem cell therapy in emerging regions is still lagging behind due to the lack of advanced medical infrastructure to adopt stem cell therapy, but the steady improvement of the healthcare sector in countries such as India and China is likely to be a major growth driver for the global stem cells market.

The increasing prevalence of neurodegenerative disorders is another major driver for the global demand for stem cells. Neural tissue can’t be regenerated or replaced as easily as structural tissues, and the ability of stem cells to develop into human cells provides the perfect avenue for treatment of neurodegenerative conditions.

High Occurrence of Unintended Pregnancy Drives the Demand for Oral Contraceptives Globally

The global oral contraceptive market has gained much prominence over years owing to a high incidence of unwanted pregnancies and various awareness programs run by governments and NGOs. Contraceptive pills, also known as birth control pills, are used in changing the hormonal cycles and preventing pregnancy. The rise in the concept of family planning has fueled the growth of the global oral contraceptive market. Moreover, the advantages of the oral contraceptive method over abortion to get rid of unwanted pregnancy helped the global oral contraceptive market in maintaining a positive growth rate.

Similarity in Composition with Natural Hormones Triggers the Growth of Combination Pills: In terms of types of products, the global oral contraceptive pills market has been divided into progestin-only pills, combination pills, and others. Combination pills are oral contraceptive pills composed of Ethinyl estradiol and progestin that are similar to natural sex hormones progesterone and estrogen produced in a woman’s body. This makes them highly efficient against pregnancy prevention, safer to use, and easily available. The composition pills can have a variable amount of estrogen level. Low level of estrogen causes less bloating or breast tenderness.

Research Report: http://www.transparencymarketresearch.com/oral-contraceptive-pills-market.html

Government Reimbursement Policies in North America Makes Contraceptive Market Growth More Favorable: In terms of geography, the global contraceptive pills market has been categorized into Europe, Latin America, Asia Pacific, North America, and the Middle East and Africa. Increased awareness about contraceptive methods and availability of beneficial reimbursement policies after implementation of the Affordable Care Act has led to the leadership of North America in the global contraceptive pills market.

Improving Economic Condition Makes Asia Pacific Opportunity-Laden Market: Asia Pacific is anticipated to rise with the highest growth rate due to strong economic growth in countries such as Australia, India, China, Philippines, Singapore, and others. High incidences of unwanted pregnancy and rapidly increasing population in countries such as India and China has led to the promotion of contraceptive methods by government and NGOs.

Moreover, the increased use of contraceptive pills to prevent pregnancy after unprotected sex will mark a growth in the oral contraceptive market globally.

Rising Prevalence of Adverse Drug Reactions Drives Global Pharmacovigilance Market

Pharmacovigilance is a crucial part of healthcare and is absolutely vital in improving the accuracy of medicine. Monitoring adverse drug reactions and evaluating the risk posed by the same to the consumers is the ambit of the pharmacovigilance industry. Pharmacovigilance is a continuous process and relies on its continuity to produce progressively more reliable results. The rising awareness about the importance of this process is leading to steady growth of the global pharmacovigilance market.

Browse Research Report: 

http://www.transparencymarketresearch.com/pharmacovigilance-market.html

An NIH study released in February this year evaluated the withdrawal of 462 medicinal products from 1953 to 2013. The report concluded that not only were the reasons for withdrawal inconsistent across the world, but there were several discrepancies in the process as well. The study recommends increased coordination within international agencies and higher transparency in reporting adverse drug reactions to improve the current scenario. A 2012 report by the NIH had also shown that there was a significant increase in the number of people suffering from adverse drug reactions in the U.S. from 1999 to 2006, with rural areas and the geriatric demographic as the key victims.

The pharmacovigilance industry is thus driven by the consistent support provided by such reviews. According to Transparency Market Research, the global pharmacovigilance market was valued at US$2.4 bn in 2013. Exhibiting a robust 14.20% CAGR from 2014 to 2020, the market is expected to rise to a valuation of US$6.1 bn.

Which is the largest product segment of the global pharmacovigilance market?

The global pharmacovigilance is segmented on the basis of clinical trial phase into phase I, phase II, phase III, and post-marketing surveillance. Of these, post-marketing surveillance or phase IV exhibited the highest utilization of pharmacovigilance procedures. 

However, the phase III segment is expected to exhibit the highest CAGR in the forecast period due to the growing realization of the importance of carrying out pharmacovigilance procedures before it is marketed. Clinical studies to remove as much harmful material as possible before the substance is put on the market are becoming increasingly important in the global pharmacovigilance industry. Nevertheless, phase IV will remain the dominant segment of the global pharmacovigilance market, since the effects of a medicinal substance may vary minutely according to the genetic profile of a particular community and can thus only be studied after the substance has been sold.

Which is the largest regional segment of the pharmacovigilance market?

Regionally, North America was the largest market in 2013 and held a 35% share in the global pharmacovigilance market. The North America pharmacovigilance market is driven by the increasing reporting of ADRs and the proactive support to pharmacovigilance practices provided by government healthcare agencies. The high technological sophistication of the healthcare sector in the U.S. and Canada also allows for easy storage of and access to ADR reports.

The Asia Pacific pharmacovigilance market is expected to exhibit the highest growth rate of all regional markets in the forecast period due to the increasing patient pool and the increasing number of clinical trials being conducted in the region. The Asia Pacific market is currently restrained by the widespread of regional alternative medicines, which usually have no provision for an equivalent of pharmacovigilance. However, this restraint is expected to be eradicated by the growing healthcare industry in countries such as India, China, and South Korea.

You can purchase and download the full report here

Global Clinical Trial Management Systems Market Welcomes the Cloud

Clinical trial management systems (CTMS) are a vital tool in medical research utilized to streamline the data collection process in clinical trials in order to make the data more easily manageable and accessible. In modern times, clinical trial management software is rapidly becoming the norm in the healthcare and pharmaceutical industry due to the increased accuracy and ease of use it provides over conventional methods of data storage. The ever-present need of medicine to have its data refined as finely as possible before clinical utilization has made clinical trial management systems a crucial tool in clinical trial protocol. 

Browse Report: http://www.transparencymarketresearch.com/clinical-trial-management-systems-market.html

The global market for clinical trial management systems is expected to reflect the rising importance of clinical trial management systems in the global healthcare sector, according to Transparency Market Research. The market intelligence firm projects a sturdy 14% CAGR for the global CTMS market from 2013 to 2019, with the market’s valuation expected to rise from US$844 mn to more than US$1.8 bn in that period. 

How influential are cloud-based clinical trial management systems for the global market?

Currently, web-based delivery of clinical trial management systems is the most popular delivery mode. However, the independent storage offered by cloud infrastructure has made cloud-based CTMS the fastest growing segment of the global market. The future of the global CTMS market is likely to feature cloud services prominently, as the global presence of cloud infrastructure improves steadily. 

Recently, global pharmaceutical giant, Pfizer, announced its plans to utilize Oracle’s cloud services across their catalog of more than 300 clinical trials every year. This allows Pfizer to focus its core power into the generation of clinical data and outsource its administration. This is an increasingly popular choice in the global pharmaceutical industry and is likely to play a determinant role in the future of the global clinical trial management systems market in the 2013-2019 forecast period.

How will the increasing investment in life sciences and pharmaceutical research affect the global CTMS market?

The increasing investment in the global pharmaceutical and life sciences sector is a major driver for the global clinical trial management systems market. The need for all kinds of commodities has grown due to the growing global population, while the increasing diversity of demographics and social and economic classes has made healthcare data increasing difficult to track. The increasing pollution and the high prevalence of the almost-stereotypically unhealthy urban lifestyle have also made various lifestyle diseases more prevalent than ever before. This has led to clinical research exhibiting a steady rise all over the world, with the global clinical trial management systems market set to benefit massively from this in the coming years. 

Which is the dominant regional segment of the global CTMS market?

Currently, North America leads the global clinical trial management systems market due to the firm establishment of several pharmaceutical industry giants in the region. However, the expanding Asia Pacific market for pharmaceutical, cosmetic, and nutritional products has made it the dominant force in the global CTMS market. The development of cloud-based smart city infrastructure in leading Asian economies such as China, India, and Japan could thus have a crucial part to play in the development of the region’s clinical trial management systems market.

You can purchase and download the full report here

Global Pain Management Therapeutics Market Restrained by Expiry of Patents, Marketing Exclusivity

Pain management therapeutics are an important class of medicines dealing with reducing and eliminating pain. Pain can originate due to several types of disorders, though tissue damage is the proximal source of pain. The wide-ranging etiology of pain, which medicine treats as a symptom rather than a condition in itself, means that pain management therapeutics have to be similarly versatile, depending on the intensity and the cause of the pain. The debilitating effect of chronic or severe pain on a patient’s quality of life is the primary reason why pain management therapeutics have become so important in modern medicine. 

According to a new report released recently by Transparency Market Research, the global pain management therapeutics market was valued at US$40.9 bn in 2011. The market is expected to exhibit a -5.5% CAGR from 2012 to 2018, ending up at a valuation of close to US$29.5 bn. 

Patent Expirations Restrict Global Pain Management Therapeutics Market

There has been a notable spike in the prevalence of conditions causing chronic pain in the last few decades. Modern phenomena such as the increasing pollution and the increasing adherence to a sedentary lifestyle have contributed to this to no small degree. This has been a major driver for the global pain management therapeutics market and will continue to be a major factor in the market’s growth trajectory in the coming years.

The expected expansion in the availability of healthcare services in emerging countries is also beneficial for the global pain management therapeutics market, as more individuals will be able to get diagnosed with and treated for chronic pain conditions.

However, the expiry of various major products in the global pain management therapeutics market, such as Lyrica (pregabalin) and Cymbalta (duloxetine) – developed by Pfizer and Eli Lilly, respectively – has hurt the prospects of the global market. The loss of marketing exclusivity of these products is likely to result in increased market prospects for generic drug manufacturers. The organized pain management therapeutics market can deal with this restraint by innovating new formulations for pain management, something the industry hasn’t achieved so far.

Browse Report: http://www.transparencymarketresearch.com/pain-management-therapeutics.html

NSAIDs Largest Product Segment, North America Major Regional Market for Pain Management Therapeutics

By product type, the global pain management therapeutics market is segmented into opioids, non-steroidal anti-inflammatory agents (NSAIDs), antidepressants, anti-migraine agents, and anticonvulsants. NSAIDs accounted for the largest share in the global pain management therapeutics market in 2011 and are likely to remain one of the largest segments of the market in the coming years.

Regionally, North America accounted for more than half of the global pain management therapeutics market in 2011, with a valuation of US$21.7 bn. Even though the North America market will remain the largest regional pain management therapeutics market in the coming years, both its valuation and its share in the global market are likely to drop over the forecast period. The North America market for pain management therapeutics is expected to be valued at close to US$14.3 bn by 2018, less than 50% of the global market’s expected 2018 valuation.

Introduction of RNA Analysis Tools and Services to Open Huge Business Prospects in Transcriptomics Technologies

There has been a shift in the focus of pharmaceuticals companies towards targeted therapeutics. This has created a demand for disease-specific biomarkers, which in turn has created opportunities in commercializing transcriptome research outcomes. Transcriptome analysis tools and services help identify novel and potential drug targets. 

Since long, the transcriptomes of stem cells and cancer cells have held the interests of researchers who strive to deeply understand how cellular differentiation or carcinogenesis take place. However, the area of study is expected to expand as researchers are now analyzing the transcriptomes of human embryos, which is expected to be a powerful tool for in vitro fertilization. Transcriptomics is thus, a technology that is continually growing in the field of biomarker discoveries and is extensively used to assess the safety of drugs. 

According to a research report by Transparency Market Research (TMR), the global transcriptomics technologies market will rise from US$1.65 bn in 2012 to US$4.6 bn by the end of 2019 expanding at a healthy CAGR of 15.90% between 2013 and 2019. 

In this blog post, TMR answers three critical questions about the global transcriptomics technologies market:

Q. What are the latest trends in the transcriptomics technologies market?

The transcriptomics technologies market is currently witnessing the partnering of many software companies with life science equipment manufacturers. The partnership is done with a vision to introduce reliable and sophisticated software, which enables easy handling of huge volumes of research data. Thus, it is expected that there will be interdependence between the IT industries and life science equipment manufacturers.

Some of the partnerships and acquisitions between IT companies and life sciences equipment manufacturers include: The acquisition of Ingenuity Systems, Inc., based in the U.S. by Qiagen N.V., has enabled web-based applications to handle the growing volumes of research data. Likewise, DNAStar, Inc., a company headquartered in Madison, has entered into an agreement with Life Technologies Corporation to market its software. 

Another trend, which is emerging in the market, is the mutual collaboration of pharmaceutical companies with research and academic institutions. The outsourcing of research in transcriptomics not only provides a good business opportunity to pharmaceutical companies, but benefits the diagnostic manufacturers as well. Such strategic moves are helping pharmaceutical and in-vitro diagnostics companies to reinforce their business presence and help increase their revenue generation.

Q. What are the challenges that the transcriptomics technologies market is expected to face?

The transcriptomics technologies market is expected to be inhibited by the rising difficulty in the management of complex data. Data complexity increases with the advancements in RNA analysis procedures. For instance, the analysis of the data acquired after the sequencing of multiple transcripts is expected to pose a major concern in transcriptomics research as it generates huge, unmanageable research findings or data. 

Dearth of inefficient data analysis tools will be another challenge impeding the growth of the market. There are very few people who have expertise in the field of transcriptomics technologies. This lack of expertise is preventing the transcriptomics technologies market to grow freely. 

Browse Report: http://www.transparencymarketresearch.com/transcriptomics-technologies-market.html

Q. What does the future hold for transcriptomics technologies?

With the introduction of RNA analysis tools and services, the next generation sequencing platform, huge business prospects are expected to open in transcriptomics research. The increasing demand for precision medicine will lead to a growth in transcriptomics research and also increase the degree of its commercialization. 

The current need for exploiting opportunities in developing novel drug discovery will give rise to assay technologies, multiplexed RNA quantification, and gene expression patterns of specific genes. Thus, the forthcoming era of transcriptomics research is expected to bring rapid advances in the field of drug discovery. As such, the price of new drugs is expected to reduce in the future and most importantly there will be elimination or reduction in the prospect of hypothesis failure. 

Global Cord Blood Banking Services Market Driven by Rising Awareness, Government Support

Cord blood banking refers to blood banks that specialize in storing stem cells from the umbilical cord blood. Cord blood and the stem cells it contains are becoming increasingly important in the global medical scenario due to the ability of stem cells to develop into various types of human cells. This ability has made their use practically imperative in several medical fields that deal with tissue and organ damage. The rising awareness about the utility of cord blood has driven the global cord blood banking services market and will continue to be a major factor in the market’s growth trajectory in the coming years.

According to a market report recently released by Transparency Market Research, the global cord blood banking services market was valued at US$12.4 bn in 2012. Exhibiting a steady 5.60% CAGR from 2013 to 2019, the market is expected to rise to a valuation of US$15.2 bn. 

What are the major drivers for the global cord blood banking services market?

Since cord blood and the stem cells that are a part thereof can only be obtained at the culmination of a pregnancy, making parents more aware of the benefits of cord blood banking has emerged as a major driver for the global market. Several developed countries have been moderately successful in educating a significant part of the population about cord blood banking, which has allowed the market to establish a firm foothold in regions such as North America and Western Europe. Not only is cord blood banking a public good, but having access to cord blood stem cells also increases the chances of the baby’s own successful recovery from various diseases at any point in its life. 

The global cord blood banking services market has also been driven by the rapid technological development observed in the sector, which has led to the process steadily becoming safer and more reliable. This has also been helped by the active role played by various healthcare bodies in spreading awareness about cord blood donation. 

Browse Report: http://www.transparencymarketresearch.com/cord-blood-banking-services.html

Why is it important to support the development of public cord blood banks?

The lack of public cord blood banks on a large scale has held the global cord blood banking services market back. While private cord blood banks store cord blood for use on the individual and their immediate family only, public cord blood banks operate as a network to supply cord blood wherever it is needed – much like a regular blood bank. While private cord blood banks are the more popular type of cord blood banks at present, public banks are expected to steadily increase in number over the next few years due to the growing government support afforded to this field.

Stem cells can help cure some of today’s deadliest and most widely prevalent diseases, such as leukemia, lymphoma, several disorders regarding proliferation of blood, and several congenital disorders. The use of stem cells in treating autoimmune diseases, cardiac diseases, and neurological diseases is also under trial and is likely to come to the fore in the coming years as long as the government support to this sector remains steady.

What are the major regional players in the global cord blood banking services market?

North America dominated the global cord blood banking services market in 2013 and is likely to retain the position over the forecast period. However, Asia Pacific is the market to be for cord blood banking market players in the coming years, as government support to healthcare upgrades is rising in this region and the increasing urban population is becoming both more aware about cord blood banking and capable of paying the relatively high prices of cord blood banking services. As prices level out over the coming years with increasing demand, Asia Pacific could well become the dominant regional market for cord blood banking services.

Reduced Drug Development Costs Steer Pharmaceutical Companies to Develop Companion Diagnostics

Pharmaceutical companies are bearing high costs involved with the development and commercialization of drugs and drug discoveries. Thus, there has been an increased focus by pharmaceutical companies on regulating the costs incurred by means of developing companion diagnostics along with therapeutic drugs. The strategy of co-development allows for the commercial availability of safe and effective drugs and thus, companion diagnostics are expected to materialize as efficient diagnostic tools that will be advantageous for pharmaceutical manufacturers. 

Get Free Sample Research Report: 

http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=387

Of late, there has been an increased demand for personalized medicines, which in turn is driving the demand for companion diagnostics, states a research report by Transparency Market Research (TMR). According to the report, the market for companion diagnostics is expected to expand at an 18.1% CAGR from 2013 to 2019.

TMR analysts answer key questions that companies operating in the companion diagnostic market need to ask:

Q. How are companion diagnostics revolutionizing patient care?

Companion diagnostics help eliminate the possibility of side effects by identifying the patients who are most likely to be at risk of several side effects by the use of a particular therapeutic drug.  They identify the patients who are most likely to benefit from a particular therapeutic drug and monitor the response of the patient to a treatment with a particular therapeutic drug. 

Monitoring patients’ response to a medicine is done to enable adjustments in the treatment, for improved effectiveness and safety. For instance, the cobas 4800 BRAF V600 mutation test, which is a companion diagnostic for vemurafenib, helps in the detection of the BRAF V600E mutation in the DNA extracted from human melanoma tissue. Developed by Roche Holdings AG, a Switzerland-based biotech company, the test is intended to be used on selected melanoma patients whose tumors carry the BRAF V600R mutation. 

Q. What are the factors challenging the growth of the companion diagnostics market?

The global companion diagnostics market is hampered to a great extent by prolonged developmental and approval period. The need to have both the drug and the device ready to be launched in the market at the same time, can potentially delay approvals. The delays in approvals of personalized medicines deprive the patients of these medicines for prolonged periods, thus hampering the uptake and sales of companion diagnostics. 

Clinical societies have a huge influence on the acceptance of companion diagnostics by end users. The views and opinions of these societies can affect the market as they impart education by giving biased opinions on their own experience with companion diagnostics. These clinical societies pose as key opinion holders and can alter the preference for companion diagnostics among patients.

Q. What is the progress in the field of companion diagnostics?

Companion diagnostics have been highly successful in the oncology area. This success is encouraging the development of companion diagnostics for other indications such as metabolism disorders, central nervous system (CNS) disorders, and infectious diseases. There have been discoveries of biomarkers for newer indication areas, which is expected to lead to a high growth and increase the revenue generation of the companion diagnostics market.

Case in point, Exosome Diagnostics, Inc. has entered into a collaboration with Takeda Pharmaceuticals International Co. to develop an exosomal RNA sequencing platform for biomarkers. With a goal to develop a platform for serial analysis of gene expression patterns beyond oncology, the analysis of RNAs will provide an innovative tool for patient characterization to select patients. It will then monitor the disease and track the response to the therapeutic drug over the time of the treatment in the patient. This biomarker platform is expected to be an effective therapy for patients not just with cancer but with CNS disorders.

Global Wound Care Market to Witness Rapid Growth on Account of Innovative Product Launches by Leading Players

The wound care market comprises several products that are used to prevent infections in the wound and accelerate the healing process. The growing awareness among the population regarding the availability of innovative products and technological advancements in the healthcare sector are contributing substantially towards the growth of the wound care market across the globe. 

In this blog, Transparency Market Research (TMR) answers several questions concerning the growth factors and major challenges faced by the key players operating in the global wound care market.

What are the major factors augmenting the growth of the global wound care market?

Governments and private healthcare organizations are spending an enormous amount on research and development activities in order to launch innovative products in the market. In addition, the growing geriatric population worldwide and growing incidences of diabetes are some of the prominent factors projected to bolster the growth of the wound care market in the next few years. Furthermore, several initiatives by healthcare service providers to create an awareness regarding wound care are expected to propel the global wound care market.

Which region is projected to grow at a rapid rate in the overall wound care market?

Among the major geographical segments, Asia Pacific is estimated to grow at a fast pace, thanks to the substantial contribution from China. In the last few years, the leading companies operating in the China wound care market have taken efforts to offer innovations and new product launches. For instance, Yunnan Baiyao Group Co Ltd introduced a new range of wound care products for different consumer groups such as cartoon plasters for children and zodiac signs printed on the products. Such trends are projected to continue in the next few years, augmenting the growth of the wound care market in China.

What are the potential growth opportunities for the major players in the global wound care market?

The chronic health disorders resulting in venous leg ulcers, diabetic ulcers, and major surgeries require different types of treatments, thus boosting the use of wound care products. This is anticipated to push up the revenue for the global wound care market in the next few years. Moreover, the substantial growth of the active wound care market and growing application of stem cell therapy in wound care are anticipated to create potential opportunities for market players in the near future. Mergers and acquisitions are further assisting the major companies in expanding their product horizon and strengthening their position in the global wound care market.

Get Free Sample Research Report: 

http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=106

What is the scope of growth in the global wound care market?

The rising incidence of several diseases across the globe offers immense growth opportunities for the players operating in the global wound care market. Some of the major companies such as Derma Sciences, Inc., Imbed Biosciences, 3M Company, Covidien PLC, Crawford Healthcare, Inc., Coloplast AS, Baxter International, Inc., and Smith & Nephew are offering a range of innovative products. 

Recently, Imbed Biosciences introduced the Microlyte wound dressing technology, which helps in killing most of bacteria on the wound’s surface and uses comparatively less silver than other products. On a similar note, Medline Industries Pvt. Ltd. also launched sterile disposable towels that are relatively more effective for wound dressing.

Growth of Global Multiple Sclerosis Drugs Market Highly Dependent on R&D Efforts of Vendors

Multiple sclerosis is a progressive, immune-mediated, neurodegenerative disorder that can also prove to be fatal. The rising incidence of multiple sclerosis around the globe and strong R&D efforts by leading players and government organizations have significantly boosted the global multiple sclerosis drugs market. 

Q. What is the current scenario of multiple sclerosis around the world?

A. According to research conducted by the Multiple Sclerosis Association of America, an estimated 2 to 2.5 million people are affected by multiple sclerosis around the globe. While the disease affects people between the age of 20 and 50, women are two or three times more likely to be affected by MS than men. A 2008 assessment of multiple sclerosis by the World Health Organization reveals that the prevalence of the condition is greatest in Europe, followed by the Eastern Mediterranean, and North America. People in high-income countries are more likely to be affected by the neurological disease; however, the WHO study emphasizes that multiple sclerosis is a global disease and not one solely of the more developed “western” countries. 

Q. How are major breakthroughs in the overall multiple sclerosis market affecting the demand for multiple sclerosis drugs?

A. The overall market for multiple sclerosis is no doubt witnessing some groundbreaking developments in recent years. In June 2016, scientists in Canada developed a radical therapy that has shown complete long-term remission from multiple sclerosis. This trial is the first in the world to halt the progression of this debilitating disease and even reverse its symptoms. The new therapy is known as immunoablation and autologous hematopoietic stem cell transplantation (IAHSCT) and involves the use of chemotherapy to completely eradicate the damaged immune system and reboot it by transfusing bone marrow cells. Some participants of the clinical trial were able to return to school, work, get married and have children, and regain the ability to drive. 

Although this trial has the potential to considerably change the course of the global multiple sclerosis market, developments such as these act as a deterrent to the multiple sclerosis drugs market. The demand for drugs have been taking a hit owing to an increasing number of MS patients opting for surgical treatments rather than drugs. 

Get a Free Sample Report: 

http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1130

Q. How is the progress of the multiple sclerosis drugs market dependent on the success or failure of major players?

A. Biogen Inc. is one of the leading companies in the global multiple sclerosis drugs market. Its performance and contribution over the years in the form of innovative and high-efficacy drugs and a strong pipeline has significantly driven the market. However, even major players such as Biogen can cause a sudden dip in the multiple sclerosis drugs market. Biogen’s experimental drug for multiple sclerosis – called opicinumab – was one of the most awaited drugs for the year and patients as well as healthcare providers were hopeful of the drug’s ability to change the course of multiple sclerosis. However, the drug failed in a mid-stage trial, missing the main as well as secondary goals for the treatment of the neurological disease. Most of Biogen’s revenue comes from MS drugs and this failure is a major setback for the company. This is also means a hitch in the progress of the global multiple sclerosis drugs market. 

Government Initiatives to Augment Growth of Global Healthcare IT Outsourcing Market

Healthcare IT outsourcing deals with the outsourcing of several IT functions to a third party in order to maintain and manage technology-related operations. The healthcare sector generates vast amounts of data, due to which it needs assistance for tracking the data electronically for billing codes, patient care, and maintaining medical records. As a result, a strong IT infrastructure, solutions, and devices are required to manage the valuable data. However, in the absence of necessary skills and IT-domain expertise, the maintenance of data becomes a crucial task for the healthcare sector. The outsourcing of several IT services helps in allowing healthcare providers to improve their service quality. 

Get a Free Sample Report: 

http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=9755

As per a research study by Transparency Market Research (TMR), the global market for healthcare IT outsourcing is projected to reach US$61.28 bn by the end of 2023. This market is expected to exhibit a 6.70% CAGR between 2015 and 2023. 

In this blog, TMR provides answers to several queries concerning the major opportunities and growth prospects in the global healthcare IT outsourcing market.

What are the primary reasons for IT outsourcing in the healthcare sector?

Nowadays, several healthcare organizations are investing enormously in IT outsourcing in order to enhance their focus on their core services and reduce management costs. Outsourcing also helps in gaining access to world-class products and services, which reduces operational costs. It takes care of several components such as financial data management, patient data management, healthcare data analytics, asset management, and several other administrative services. Moreover, the adoption of IT outsourcing helps in dealing with rising concerns related to data security and consolidates the overall healthcare system.

What are the major developments in the global healthcare IT outsourcing market?

Governments are encouraging healthcare reforms such as International Statistical Classification of Diseases and Related Health Problems (ICD-10) norms, Affordable Care Act (ACA), Health Insurance Exchange (HIX), and Medicare, which have led to increased adoption of IT outsourcing services in the healthcare sector. In addition, the leading players including Accenture Plc., Infosys Limited, McKesson Corporation, IBM Corporation, Allscripts Healthcare Solutions, Inc., and Cognizant Technology Solutions are making continuous efforts to offer advanced IT services to the healthcare sector. For instance, Cognizant has come together with Orion health to develop a cloud platform to allow new levels of payer, provider, and consumer collaboration. 

Browse Press Release:

http://www.transparencymarketresearch.com/pressrelease/healthcare-it-outsourcing-market.htm

What are the potential growth opportunities for the major players in global healthcare IT outsourcing market?

Healthcare infrastructure has been developing across the globe resulting in high demand for cost-effective IT services. In addition, the booming medical tourism in developing economies has created several opportunities for the major players operating in the global healthcare IT outsourcing market. The growing government interventions to provide the consumers with technology-driven and cost-efficient healthcare services are further expected to boost the demand for healthcare IT outsourcing services in the next few years. Furthermore, the increasing healthcare expenditure and growing patient population worldwide pushes the requirement to outsource IT solutions for enhanced healthcare management.

Future of Global Animal Healthcare Market to be Shaped by Impact of Animal Health on Quality of Dairy Products

The animal healthcare market has undergone a transformation, solving the grievances of pet owners and saving the cattle that is integral to the poultry industry. This market has been an answer to a wide array of health issues faced by animals that are domesticated or reared. For instance, the revolutionary transformation of agrochemical pesticides into safe and effective topical applications for treating ticks and flea made owning pets a cleaner deal. 

You can download a sample for free:

http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2446

Simple changes, such as lacing treats with medications, which bridged the gap between meting out treatments to animals that do not have the intelligence of taking timely dosages have been instrumental in driving the animal healthcare market. Beyond these changes that may seem simple are some of the remarkable innovations. The global animal healthcare market has been riding on the ground-breaking therapeutics devised by industry experts and a growing interest among caregivers to adopt these treatments. 

Q. What will drive the progress of global animal healthcare market?

A. A recently published report by Transparency Market Research states that the global animal healthcare market will reach nearly US$41.93 bn by the end of 2019 from US$27.86 bn in 2013. The market is expected to expand at a steady CAGR of 7.1% from 2014 to 2019. Besides the economic and social forces steering the future of the global animal healthcare market, consistent innovations by key operating players will also have a significant impact.

Elanco Products Company, Vetoquinol, Boehringer Ingelheim Gmbh, Virbac SA, Merck & Co. Inc., Ceva Sante Animale, Novartis Animal Health Inc., Merial Ltd., Zoetis Inc., and Bayer AG are some of the important companies in the overall animal healthcare market. Analysts predict that burgeoning demand for dairy products and a high incidence of diseases in animals and the contraction of the same by humans are expected to drive this market in the foreseeable future.

Q. How will the feed additives segment drive the global animal healthcare market?

A. Needless to say, innovation will push the global animal healthcare market, outlining certain segments of the veterinary sector. For instance, the feed additives segment holds the biggest share in the overall market due to a sudden boom in the animal population. Feed additives play a significant role in the growth and development of livestock, which in turn is closely related to human nutrition. Owing to this, several breeders and manufacturers are developing enhanced nutritional solutions that boost the quality of life of animals and their well-being.

Q. Which geographical segment will lead the global market during the forecast period?

A. As of 2013, North America held a share of 31.7%, which was followed by Asia Pacific and Europe. Research suggests that North America will continue to retain its leading position in the overall market all through 2019. However, Asia Pacific is anticipated to surpass this market share due to the increasing poultry and livestock farming projects and rising trend of pet adoption. The improving disposable incomes in China and India are also expected to drive the success of the animal healthcare market in Asia Pacific in the coming years. 

Browse Press Release: 
http://www.transparencymarketresearch.com/pressrelease/global-animal-healthcare-industry.htm

Though the investments pumped into the animal healthcare market pale when compared to those made in human healthcare, the former will thrive due to the growing awareness of the relationship between the two. Furthermore, the role of animal healthcare in food security solutions will also boost this market in the near future.